Mölnlycke US. Revenue and Competitors

Atlanta, GA USA

Location

N/A

Total Funding

Estimated Revenue & Valuation

  • Mölnlycke US.'s estimated annual revenue is currently $83.3M per year.(i)
  • Mölnlycke US.'s estimated revenue per employee is $251,000

Employee Data

  • Mölnlycke US. has 332 Employees.(i)
  • Mölnlycke US. grew their employee count by 5% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$7.3M29N/AN/AN/A
#2
$104.7M4173%N/AN/A
#3
$6M24-23%N/AN/A
#4
$5M400%$16MN/A
#5
$6M24-23%N/AN/A
#6
$10.8M435%N/AN/A
#7
$3M240%$50MN/A
#8
$10M40-13%N/AN/A
#9
$5M2011%N/AN/A
#10
$17.6M703%N/AN/A
Add Company

What Is Mölnlycke US.?

A world-leading medical solutions company We design and supply medical solutions to enhance performance in healthcare – from the hospital to the home. Around the world, healthcare systems and professionals are under pressure to deliver better care, to more people, for better value. They need innovative solutions they can trust. That’s where we come in. We’re here to advance performance in healthcare. So we’re always on the lookout for new ways to improve. Our focus: providing effective solutions and offering better value for money. Solutions to improve outcomes We have one purpose – to advance performance in healthcare across the world. So that healthcare professionals have what they need to achieve the best clinical, patient and financial outcomes. But different healthcare professionals have different needs. So we start by listening and making sure we understand them. Then we create solutions that are right for them and for their patients, and that are supported by evidence. We contribute to advancing performance in other ways too. By sharing knowledge about our specialist clinical areas. And by helping to shape healthcare policies and protocols to raise standards of care worldwide. We have a strong commitment to healthcare professionals. And we’re proving it every day. A global company with a Swedish heritage Customers use our solutions in almost 100 countries – and we own operations in more than 40 of them. Although we’re a global company, our headquarters are still in Gothenburg – just a short distance from the town of Mölnlycke (pronounced 'Mon-licka'?). The place where the company was founded in 1849 and the origin of the Mölnlycke name. Disclaimer: Products shown may not be available in all countries or may be known by a different name. Indications for use and product claims may vary from country to country.

keywords:N/A

N/A

Total Funding

332

Number of Employees

$83.3M

Revenue (est)

5%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Mölnlycke US. News

2022-04-20 - Global Wound Care Products Market 2022 Industry Growth ...

(U.S.); Smith and Nephew Plc. (U.K); Integra Lifesciences Corporation (U.S.); Molnlycke Health Care (Sweden); ConvaTec, Inc. (U.S.)...

2022-04-19 - Antimicrobial Dressings Market Size, Scope And Forecast | 3M ...

New Jersey, United States – The Antimicrobial Dressings Market report is the ... 3M, Molnlycke Health Care, Smith & Nephew, Kinetic Concepts...

2021-11-15 - Mölnlycke Health Care Donates 1.9 Million N95 Particulate Respirators to Operation Smile

For Operation Smile, Mölnlycke’s donation will allow more medical volunteers to safely provide surgery, comprehensive care and training for local health workers. VIRGINIA BEACH, Va. (PRWEB) November 15, 2021 In collaboration with fellow Partnership for Quality Medical Donations (PQMD) member o ...

2020-10-15 - Mölnlycke launches new skin-friendly Biogel® surgical gloves to reduce the risk of allergic contact dermatitis for surgeons and nurses

NORCROSS, Ga., Oct. 15, 2020 /PRNewswire/ -- Mölnlycke is celebrating World Handwashing Day with the launch of the innovative Biogel® PI UltraTouch® S surgical glove, which addresses the problem of allergic contact dermatitis among surgical teams. Frequent handwashing and exposure to chemicals ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$135.6M3389%N/A
#2
$103M33930%N/A
#3
$64M353N/AN/A
#4
$143.3M355-5%N/A
#5
$150.3M370N/AN/A